You have never encounter the Epstein-Barr virus at all in your entire life. But it has all the information about you

 And in all likelihood it is fermenting in your bowels right now at this very time. According to some estimations, about 95 per cent of the adults in America are affected by this virus at some stage in their careers. Moreover, after contamination to the virus, the virus is with the person for his or her entire life span. 

 With most viruses for instance the flu they just emerge n and then fade after sometime and this was what most people expected to happen with the new virus. A healthy immune system is the one that recognizes them, counters them, kills them and ensure that one is not infected with them again. Epstein-Barr and its relatives that include herpes, those that causes chickenpox can comfortably stay in your body cells for 30 years plus.

 ‘They are known to have co-adapted with us for millions of years,’ said Blossom Damania, a virologist at the University of North Carolina-Chapel Hill in the United States. “For one, they know all your body’s secrets. ” 

 While childhood antibodies are usually asymptomatic, contact in teenagers and younger grownups develops into infectious mononucleosis, a weeks-long sickness that affects 125000 Americans every year and is characterized by sores in the throat, swollen glands, and constant tiredness. Epstein-Barr is usually dormant and tends to be sleepy for most of the year but it can reactivate during stress or possibly a low immune system. Those reactivation is associated with a variety of severe illnesses such as several types of cancer and autoimmune diseases. 

 Researchers have dedicated their efforts in the last twenty years to create vaccines against Epstein Barr virus, or EBV. The search has gotten more emphatic over the recent past due to several advances in medical research — and potential of attaining the breakthrough. Two potential vaccine projects have proceeded all the way to human trials within the past one year.

What’s changed? 

 First, the ethnographic research exposed the fact that there is a much more dangerous virus, namely the Epstein-Barr virus. New evidence clearly establishes that it is directly connected with multiple sclerosis or MS, a serious progressive condition that affects more than 900,000 people in the United States and 2. 8 million people worldwide. 

 Readers of Science journal in January got to learn about a research outcome of a study involving 10 million military personnel that was conducted over 20 years, and it provides the most compelling evidence that Epstein-Barr can cause MS. In the new study it was discovered that for those people who are infected with Epstein-Barr virus they are 32 percent more likely to be diagnosed with Multiple Sclerosis as compared to those people not infected with the virus. 

 And finally another team of researchers unveiled how the virus can trigger an autoimmune response that results in MS, work that shed new light on the mechanisms that could explain that correlation. The disease also develops between the ages 20 and 40 and affects the flow of information between the brain and the rest of the body; the symptoms include fluctuations in muscle strength, and episodes of fatigue, blurred vision, muscle and coordination problems. Worse case, MS may cause the patient to be in a wheelchair or lose speech capability due to paralysis of some muscles of the body. 

 Even more reinforcing that newfound urgency, several new studies also indicate that reactivation of the Epstein-Barr virus also is associated with some instances of long covid, a still-not-well-understood ailment in which patients continue to suffer from symptoms akin to mononucleosis long after their initial covid bout. 

 And just as crucial to the momentum: The advancements in vaccines caused by covid such as the mRNA used in some covid vaccines could enhance the development of other vaccines such as Epstein Barr, according to Dr. Peter Hotez, the dean of the National School of Tropical Medicine at Baylor College of Medicine. Hotez co-developed a very cheap covid vaccine known as Corbevax and does not have any patent claims. 

 That is why some researchers argue that the utility of developing a vaccine for the disease like MS that though significantly disabling, is not widespread. 

In other words, to eradicate Epstein-Barr, everyone would need to be vaccinated even though the children that are healthy at the moment would, at some point in their lives, develop either cancer or multiple sclerosis, said Dr. Ralph Horwitz of the Lewis Katz School of Medicine at Temple University. 

 He said that before children are put in front of potentially hazardous effects of a new vaccine, scientists should ask simple questions regarding MS. For instance, why does a virus that infects practically all the people lead to disease in a few? But what part of that equation is played by stress and other conditions existing in the environment? 

 The answer seems to lie in the fact that Epstein-Barr is “necessary but not sufficient” for disease, according to immunologist Bruce Bebo, the executive vice president for research at the National MS Society The virus “may be the first in a string of dominoes. 

 The System Service said Hotez noted that while researchers could keep investigating the mysteries about Epstein-Barr and MS, the vaccine efforts would also go on. More research needs to be conducted to identify which populations might benefit most from the vaccine; when more is known, Hotez said, such a vaccine probably could be used in patients found to be at highest risk, such as those with organ transplants, rather than given routinely to all young people. 

 “Now that we know that Epstein-Barr is very tightly linked to MS, we could save a lot of lives if we develop the vaccine now,” Damania said, “rather than wait 10 years”. 

Modern and National Institute of Allergy and Infectious Diseases have initiated two different clinical trials on Epstein-Barr vaccines in the last one year. Epstein-Barr vaccines also are in the preliminary stage at Miami-based Opko Health, Inc. , the Seattle based Fred Hutchinson Cancer Center and City of Hope National Medical Center in California. 

Researchers have expended a great amount of efforts towards the discovery of vaccines for Epstein-Barr just for them to discover the robust nature of the virus. Epstein-Barr “is a master of evading the immune system,” Scott said; Jessica Durkee-Shock, a clinical immunologist and principal investigator for NIAID’s trial. 

 MS and the cancers associated with Epstein-Barr take years to appear in people after they have been infected. Thus, a trial that is meant to find out if a vaccine can eradicate these diseases would have taken ages and a lot of cash. 

 Moderna researchers initially are focusing on a goal more easily measured: It helps to prevent mononucleosis, which increases the chances of a person developing multiple sclerosis by two times. Mono appears one or two months after Epstein-Barr virus infects individuals; scientists won’t have to wait for too long to get results. 

 Even when the virus is single stranded it is not isolated and can be extremely troublesome robust enough to send students home from school and military recruits from basic training for weeks. In approximately 10 % of cases the disabling fatigue persists for more than six months. 1% of patients experience side effects and these may include health issues such as hepatitis and neurological disorders. 

 At the current moment, the testing of Epstein-Barr vaccinations is only open to adults and participants of clinical trials. “In the future, the perfect vaccine would be given to a small child”, Durkee-Shock. “And it would protect them their whole life and any form of complication arising from the Epstein-Barr virus such as obtaining the mono vitamins. ” 

 The NIAID vaccine which is still in experiments for safety in 40 volunteers is based on ferritin, an iron-storage protein that can be engineered to show immune system a key viral protein. In the manner of the cartoon Transformer, the ferritin nanoparticle transforms itself into what appears to be a ‘little iron soccer ball’ Durkee-Shock said. “This approach where numerous copies of the EBV protein are presented on the same particle has been tried in other vaccines, including the HPV as well as the hepatitis B vaccines. ” 

Moderna’s experimental vaccine it is trialing in roughly 270 participants is closer to the company’s covid shot. Both DO require packets of a virus’s genetic code in molecules known as mRNA inside a lipid nanoparticle, or tiny bubble of fat. Moderna has approximately 33 mRNA vaccines in the pipeline, and Epstein-Barr is no exception that it expects different challenges and opportunities in each of the vaccines it is working on, said Sumana Chandramouli, Senior Director and Research Program Leader for Infectious Diseases at Moderna. 

 “What the covid vaccine has taught us is that the Information roaming mRNA technology is well tolerated, very safe, and highly efficacious,” Chandramouli said. 

 However, there is a certain drawback of mRNA vaccines. 

 While they saved millions of lives during the covid pandemic, the antibodies that the body is producing in response to the mRNA vaccines wore off after a few months. There could be a superimposition of this high rate of shedding of antibodies to the coronavirus, which is itself producing new strains that evolve very quickly, Hotez pointed out. But if decline in immunity is inherent in this Mrna technology, that can be very much dangerous for the future vaccines. 

 Developing vaccines against Epstein-Barr is also not easy when compared to covid vaccines. Epstein-Barr virus and other herpesviruses are large in comparison, and four to five times the size of SARS-CoV-2, the virus that causes Covid. while coronavirus utilize only one protein to enter human cells, Epstein-Barr virus uses many and four of them are present in Moderna vaccine. 

 Prior experimental Epstein-Barr vaccines geared toward one viral protein decreased the incidence of infectious mononucleosis but did not prevent viral disease. Perhaps broad-spectrum virus inhibitors, or those specific for various viral proteins, may offer better protection said Damania the virologist from UNC. 

 “So, if you shut one door, the other door is always open,” Damania said. “Saying that, it is only possible to think that only effector and, maybe, B-cells have to be prevented from infection for the vaccine to be effective in preventing subsequent infections. ” 

KHN (Kaiser Health News) is a nonprofit newsroom that reports on health care in the United States in terms of specialties, geography, politics, and demographics. Kaiser Family Foundation or KHN is one of the key three operating programs that it has; the other two are Policy Analysis and Polling. KFF is a nonprofit organization that is endowed to offer information on health problems in the nation. 

Sources:

American College of Cardiology

American Congress of Obstetricians and Gynecologists

The Centers for Disease Control and Prevention

Epocrates

Bladgo